Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Inclusion Criteria: * Males and females ≥ 18 years. * Diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, considered incurable with standard therapy. Diagnosis will have been confirmed using a biopsy of the tumour. * Patients having, based on the investigators judgment, had disease progression and for whom curative therapy is not possible. * Patients with a WHO performance status ≤ 2 and a life expectancy of greater than 3 months. * Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out. Exclusion Criteria: * Patients previously treated with any Epidermal Growth Factor Receptor (EGFR) targeted therapy such as anti-EGFR monoclonal antibodies or small molecule inhibitors within 6 months prior to visit 2 (first treatment). * Received the following treatments within 4 weeks prior to Visit 2 (first treatment): * Cytotoxic or cytostatic anticancer chemotherapy * Total tumor resection * Radiotherapy of \> 50 Gy to gross tumor volume * Chronic or current infectious disease such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, sinusitis, and tuberculosis * Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from Visit 1 (screening), congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities * Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease * History of significant cerebrovascular disease * Known HIV infection * Known hepatitis B and/or hepatitis C * Screening laboratory values: * Neutrophils \< 1.5 x109/l * Platelets \< 75 x109/l * ALAT \> 2.5 times the upper limit of normal (unless known liver metastases exceptions will be dealt with on a case by case basis) * ALP \> 2.5 times the upper limit of normal (unless known liver metastases exceptions will be dealt with on a case by case basis) * Bilirubin \> 1.5 times the upper limit of normal * Creatinine clearance \< 50 ml/min (measured or calculated by the CockgroftGault method) * Patients who have received treatment with any non-marketed drug substance within 4 weeks before Visit 1(screening) * Current participation in any other interventional clinical study * Patients with a BMI ≥ 30 kg/m2 * Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder) * Breast feeding women or women with a positive pregnancy test at Visit 1 (screening) * Women of childbearing potential not willing to use adequate contraception such as hormonal birth control or intrauterine device during study.